CLDN18 and gastric cancer: In esophageal and gastric cancers, targets such as HER2 (NCT02713984), EGFR, CEA (NCT02349724), MSLN (NCT03747965), CLDN18.2 (NCT05472857), and NKG2D have shown effective antitumor effects in preclinical and early clinical trials.